Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OncoGenex/Teva Alter Late-Stage Custirsen Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Teva and OncoGenex announced changes to the Phase III program of their prostate cancer drug custirsen on the heels of positive data from a competitor.

You may also be interested in...



Earnings Updates, In Brief: Vitae, OncoGenex, Cara

Vitae and partner Boehringer Ingelheim to start over in Alzheimer’s with new compound, shelving lead drug due to skin reactions. OncoGenex sees subgroup data providing a potential niche indication for custirsen, while Cara is ready to begin Phase III with its intravenous candidate for post-surgical acute pain.

Financings Of The Fortnight Sees The Blooming Of New Life Sciences Funding Sources In The EU

Plus news on recent financing activity by Aastrom Biosciences, Tarsa Therapeutics, OncoGenex and Medivation.

OncoGenex Raises Cash For Prostate Cancer Trials

OncoGenex raises $50 million in cash to support the development of its earlier stage oncology assets.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073863

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel